Moderna Swings to Profit, Lifts Outlook as Covid-19 Vaccine Demand Stabilizes

Moderna returned to profitability in the latest quarter and raised its full-year revenue forecast, defying Wall Street expectations for continued losses. The Wall Street Journal reports that international demand for the company's Covid-19 shots stabilized, driving the swing.

The higher outlook follows U.S. approval of Moderna's mRNA-based influenza vaccine. That approval gives the company a second commercial product in a major market, which may explain why management felt comfortable lifting guidance. (This is interpretation: the source ties the raised outlook to the approval but does not break out any revenue contribution from the flu vaccine.)

The setup matters for positioning. Consensus expected losses, so a profit is a clean earnings beat on the headline line, and a raised revenue forecast compounds it. A beat paired with higher guidance is the combination that typically forces analysts to revise models upward, though the source gives no figures on the size of the profit or the new forecast range.

The stabilization in Covid-19 demand is the key detail. For a company whose revenue has been dominated by Covid shots, evidence that international demand has leveled off addresses the core bear thesis around a shrinking base business. Whether that stability holds is the open question.